An in-depth analysis of the effects of cardamonin, 2Ј,4Ј-dihydroxy-6Ј-methoxychalcone, on rat tail artery preparations was performed by means of whole-cell patch-clamp recordings of Ca v 1.2 Ca 2ϩ [I Ca(L) ] or Ba 2ϩ [I Ba(L) ] current as well as K Ca 1.1 currents in single myocytes and by measuring contractile responses in endothelium-denuded isolated rings. At a holding potential (V h ) of Ϫ80 mV, cardamonin decreased both I Ba(L) and I Ca(L) in a concentration-dependent manner with similar pIC 50 values. The maximum of the I Ba(L) -voltage relationship was shifted by 10 mV in the hyperpolarizing direction, but threshold remained unaffected. Cardamonin modified both the activation and the inactivation kinetics of I Ba(L) and shifted the voltage dependence of both inactivation and activation curves to more negative potentials by 19 and 7 mV, respectively, thus markedly decreasing the Ba 2ϩ window current. Block of I Ba(L) was frequency-dependent, and rate of recovery from inactivation was slowed. Cardamonin increased K Ca 1
cies (Israf et al., 2007) . To date, very few biological effects have been ascribed to this compound. Cardamonin is known to inhibit collagen-, arachidonic acid-, and adenosine diphosphate-induced platelet aggregation of human whole blood (Doug et al., 1998) and to prevent mutagenicity promoted by the metabolic activation of heterocyclic amines (Trakoontivakorn et al., 2001; Nakahara et al., 2002) . It also possesses appreciable in vitro anti-HIV (Tewtrakul et al., 2003) as well as anti-dengue 2 virus activity (Kiat et al., 2006) . In addition, cardamonin shows potent in vitro as well as in vivo antiinflammatory properties due to its ability to inhibit lipopolysaccharide-induced inducible nitric-oxide synthase expression and to suppress the production of pro-inflammatory cytokines such as tumor necrosis factor ␣ (Hatziieremia et al., 2006; Lee et al., 2006; Israf et al., 2007) . These observations have provided the rational basis for the use, for example, of Alpinia conchigera Griff (Zingiberaceae) rhizomes in Vietnamese folk medicine for treatment of inflammatory diseases (Vo, 1997) . Furthermore, recent reports have demonstrated that cardamonin induces both endothelium-independent and endothelium-dependent relaxation, the latter developing primarily through endothelial NO release (Huang et al., 2000; Wang et al., 2001) .
In systemic hypertension, vascular remodeling contributes to increase peripheral resistance, affecting the development of and complication in hypertension. Many factors, such as low-grade inflammation triggered in part by increased oxidative stress, seem to play a role in the process leading to remodeling of small and large arteries in hypertension (Intengan and Schiffrin, 2001) . Recently, the so-called "endothelial dysfunction," which is associated with various types of cardiovascular disease, has been described to be characterized by reduced NO production and oxidative overload, as well as a proinflammatory state (Endemann and Schiffrin, 2004) .
The vasorelaxing agent cardamonin, in possessing both antioxidant and anti-inflammatory properties, might represent a useful drug for treating systemic hypertension and, specifically, those diseases associated with endothelial dysfunction. The mechanism involved in cardamonin-induced endothelium-independent relaxation, however, has not yet been elucidated. Based on indirect evidence, Wang et al. (2001) hypothesized that this compound induces vasorelaxation by reducing Ca 2ϩ influx through voltage-dependent Ca 2ϩ channels. Furthermore, the effect of cardamonin on K Ca 1.1 channels, which limit depolarization and vasoconstriction, thus playing an important role in the control of myogenic tone in vascular smooth muscle (Nelson and Quayle, 1995) , has not previously been investigated. Accordingly, the present study aimed to investigate the effects of cardamonin on both Ca v 1.2 and K Ca 1.1 channels in the rat tail artery.
Materials and Methods
Animals. This investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH Publication 85-23, revised 1996) , and the animal protocols used were reviewed and approved by the Animal Care and Ethics Committee of the Università degli Studi di Siena, Italy (31-1-2006) . Male Sprague-Dawley rats (300 -400 g; Charles River Italia, Calco, Italy) were anesthetized intraperitoneally with a mixture of Ketavet (30 mg/kg ketamine; Gellini, Aprilia, Italy) and xylazine (8 mg/kg Xilor; Bayer AG, Wuppertal, Germany), decapitated, and bled. The tail was removed immediately, cleaned of skin, and placed in physiological salt solution (see below for composition). The main tail artery was dissected free of its connective tissue. To perform 2 days of experiments with only one rat [day 1 I Ca(L) and day 2 K Ca 1.1 current], two different enzyme systems were used to isolate cells from the tail artery. Collagenase performed acute dissociation of cells to be used on the same day of sacrifice, whereas papain for overnight digestion yielded cells used the 2nd day. K Ca 1.1 currents recorded on cells harvested after an overnight digestion are known to possess biophysical and pharmacological features identical to those recorded in acutely isolated cells (for example see Petkova-Kirova et al., 2000) , whereas no data are available for I Ca(L) recorded in myocytes isolated 24 h after the sacrifice. Consequently, I Ca(L) was recorded on day 1 cells (collagenase), and K Ca 1.1 current was recorded on day 2 cells (papain).
Cell Isolation Procedure for I Ca(L) Recordings. Smooth muscle cells were freshly isolated from the tail main artery incubated at 37°C in 2 ml of 0.1 mM Ca 2ϩ external solution (see below for composition) containing 1 mg/ml collagenase (type XI), 1 mg/ml soybean trypsin inhibitor, and 1 mg/ml BSA, gently bubbled with a 95% O 2 , 5% CO 2 gas mixture, as described previously . Cells exhibited an ellipsoid form (10 -15 m in width, 35-55 m in length) and were continuously superfused with external solution containing 0.1 mM Ca 2ϩ and 30 mM tetraethylammonium using a peristaltic pump (LKB 2132; Bromma, Sweden) at a flow rate of 400 l/min. Cell membrane capacitance averaged 40.53 Ϯ 1.46 pF (n ϭ 49) and was not affected by the application of cardamonin. The of the voltage-clamp averaged 0.52 Ϯ 0.05 ms (n ϭ 49).
Cell Isolation Procedure for K Ca 1.1 Current Recordings. Smooth muscle cells were isolated from the tail main artery stored overnight at 4°C in 1 ml of solution for enzymatic cell isolation containing 1.5 mg papain, 0.4 mg of DL-dithiothreitol, and 1.6 mg of BSA and incubated, the day after, for 5 to 15 min at 37°C in the abovementioned solution, gently bubbled with a 95% O 2 , 5% CO 2 gas mixture, as described previously (Saponara et al., 2006) . Cells, characterized by an elongated shape (8 -12 m in width, 40 -50 m in length), were continuously superfused with the recording solution at a flow rate of 400 l/min using a peristaltic pump (LKB 2132; Bromma, Sweden). Cell membrane capacitance averaged 22.72 Ϯ 1.56 pF (n ϭ 34) and was not affected by the application of cardamonin. The of the voltage-clamp averaged 0.32 Ϯ 0.03 ms (n ϭ 34).
Whole-Cell Patch-Clamp Recordings. The conventional wholecell patch-clamp method (Hamill et al., 1981 ) was employed to voltage-clamp smooth muscle cells. Recording electrodes were pulled from borosilicate glass capillaries (WPI, Berlin, Germany) and firepolished to obtain a pipette resistance of 2 to 5 M⍀ when filled with internal solution (see below). A low-noise, high-performance Axopatch 200B patch-clamp amplifier (Molecular Devices Corporation, Sunnyvale, CA) driven by a personal computer in conjunction with an A/D,D/A board (DigiData 1200 A/B series interface; Molecular Devices Corporation) was used to generate and apply voltage pulses to the clamped cells and record the corresponding membrane currents. At the beginning of each experiment, the junction potential between the pipette and bath solutions was electronically adjusted to zero. Cell break-in was accomplished by gentle suction at a holding potential (V h ) of either Ϫ40 or Ϫ50 mV for K Ca 1.1 current recordings and for I Ca(L) and I Ba(L) recordings, respectively. V h then was set to Ϫ80 mV [I Ca(L) and I Ba(L) recordings]. Micropipette seals had to be G⍀ in nature with leak currents less than 0.25 pA/mV. Current signals, after compensation for whole-cell capacitance and series resistance (between 70 and 80%), were low-pass filtered at 1 kHz and digitized at 3 kHz before being stored on the computer hard disk. Electrophysiological responses were tested at room temperature (20 -22°C) only in those cells that were phase-dense. The findings presented here, obtained with the traditional whole-cell patch-clamp technique, may not necessarily reflect normal cellular physiology because of cytoplasmic disruption, nonphysiological ionic concentrations, artificial Ca 2ϩ buffering, and loss of soluble signaling molecules during dialysis.
I Ca(L) and I Ba(L) Recordings. Cells used in this study expressed Ca v 1.2 but not Ca v 3.1 channels (see Petkov et al., 2001 Current was elicited with 250-ms clamp pulses (0.067 Hz), either to 0 mV or to 10 mV, from a V h of Ϫ80 mV until a stable current response was achieved (usually 7-10 min after the whole-cell configuration had been obtained). At this point, the various protocols were performed as detailed below. Both I Ba(L) and I Ca(L) did not run down over the next 20 to 30 min under these conditions (Petkov et al., 2001) .
Current-voltage relationships were fitted with the equation I Ba ϭ G Ba (1/1 ϩ exp((E 50 Ϫ E m )/k)) (E m Ϫ E rev ), where G Ba is the maximal available conductance, E 50 is the membrane potential at half-maximal current activation, E m is the membrane potential, k is the slope factor, and E rev is the reversal potential. Steady-state inactivation curves, recorded twice from the same cell (in absence and presence of the drug, respectively), were obtained using a double-pulse protocol. Once various levels of the conditioning potential had been applied for 5 s, followed by a short (5 ms) return to the V h , a test pulse (250 ms) to 0 mV was delivered to evoke the current. Under control conditions, the 50% inactivation potential evaluated by fitting a Boltzmann distribution to the first curve was not significantly different from that of the second curve recorded after 10 min (see Fusi et al., 2002) .
Activation curves were derived from the current-voltage relationships (see Fig. 3 ). Conductance (G) was calculated from the equation G ϭ I Ba /(E m Ϫ E rev ), where I Ba is the peak current elicited by depolarizing test pulses in the range of Ϫ50 to 10 mV from V h of Ϫ80 mV, E m is the membrane potential, and E rev is the reversal bi-ionic potential (166 mV, as estimated with the bi-ionic equation assuming a permeability ratio P Ba /P Ca for Ca v 1.2 channels of 0.4; see Hille, 2001) . G max is the maximal Ba 2ϩ conductance (calculated at potentials ՆϪ10 mV). The ratio G/G max was plotted against the membrane potential and fitted with the Boltzmann equation.
The window current was calculated by multiplying the activation conductance curve by the inactivation curve as previously reported by Chemin et al. (2000) . Permeability (P S ) was derived from the Goldman-Hodgkin-Katz current equation. A two-pulse protocol was applied to measure the time course of recovery from inactivation: 2-s clamp pulses to 0 mV from a V h of Ϫ80 mV were followed by a return to the V h of variable duration to allow some channels to recover from inactivation. A second pulse (250 ms) to 0 mV was delivered to determine how much recovery had occurred during the time interval. K ϩ currents were blocked with 30 mM tetraethylammonium in the external solution and Cs ϩ in the internal solution (see below). Current values were corrected for leakage using 300 M Cd 2ϩ , which was proven to block completely I Ba(L) and I Ca(L) . Following control measurements, each cell was exposed to cardamonin by flushing through the experimental chamber solution containing the drug.
K Ca 1.1 Current Recordings. K Ca 1.1 recordings were performed in the presence of nicardipine, a Ca v 1.2 channel blocker, as well as at low external Ca 2ϩ concentration (i.e., 0.1 mM) to minimize the contribution of extracellular Ca 2ϩ influx to the current recorded. K Ca 1.1 current was measured over a range of test potentials (500 ms) from Ϫ20 to 100 mV from a V h of Ϫ40 mV. Data were collected once the current amplitude had been stabilized usually 8 to 10 min after the whole-cell configuration had been obtained. K Ca 1.1 current did not run down over the next 20 to 30 min under these conditions (Saponara et al., 2006) . Current values were corrected for leakage using 100 nM iberiotoxin, a specific blocker of K Ca 1.1 currents (Wei et al., 2005) .
Contraction Experiments. Cardamonin was tested on rat tail artery rings to assess its possible vasodilating effect. The endothelial layer was removed by inserting and gently rolling a stainless steel wire on the intimal surface of the vessel. Two-millimeter wide rings were mounted, under a preload of 1.5 g, using 40-m tungsten wires inserted inside the lumen in a home-made Plexiglas support connected to an isometric force transducer (2B Biological Instruments, Varese, Italy) connected to a pen recorder (Ugo Basile, Comerio, Italy). The preparations were immersed in 20-ml organ baths containing a physiological salt solution (see below), thermostated at 37°C, and continuously gassed with a mixture of O 2 (95%) and CO 2 (5%). After an equilibration period of 60 min, the absence of functional endothelium was assessed by verifying the lack of 1 M carbachol-induced relaxation in rings precontracted with 1 M phenylephrine. Rings were then contracted with either 1 M phenylephrine or 10 M (S)-(Ϫ)-Bay K 8644, and when the contraction reached a plateau, cumulative (1-50 M) concentrations of cardamonin were added. Because Ca 2ϩ channel activators, such as (S)-(Ϫ)-Bay K 8644, evoke contractile tonic responses in vascular smooth muscle preparations only when they are partially depolarized with low K ϩ concentrations (Fusi et al., 2003) , in these experiments, the K ϩ concentration of the physiological salt solution was increased to 20 mM. Some experiments were performed in the presence of the K ϩ channel blocker iberiotoxin (100 nM). This blocker was added into the organ bath when the contractile effect induced by phenylephrine or (S)-(Ϫ)-Bay K 8644 reached the plateau and was allowed to equilibrate with tissues for 30 min before the addition of cardamonin.
Wash-out of cardamonin was studied in rings stimulated with phenylephrine. After a reproducible response to phenylephrine was obtained, rings were preincubated with cardamonin for 30 min and then stimulated with 1 M phenylephrine in the presence of the drug. Responses to phenylephrine in the absence of the drug, interrupted by 30-min washout periods with physiological salt solution, were then repeated for 150 min.
Materials. Cardamonin (2Ј,4Ј-dihydroxy-6Ј-methoxychalcone), obtained in crude form as a precipitate from the hexane extract of the leaves of Combretum apiculatum Sond. (Combretaceae), was purified by recrystallization from methanol-dichloromethane and identified by comparison of its spectral data with literature values (Koorbanally, 2001 ). The chemicals used included collagenase (type XI), trypsin inhibitor, BSA, tetraethylammonium chloride, papain, DL-dithiothreitol, iberiotoxin, EGTA, BAPTA, taurine, nicardipine, carbachol, phenylephrine, (S)-(Ϫ)-Bay K 8644, and CdCl 2 (Sigma Chimica, Milan, Italy). Nicardipine dissolved directly in ethanol, cardamonin, and (S)-(Ϫ)-Bay K 8644, dissolved directly in dimethyl sulfoxide, were diluted at least 1000 times before use. The resulting concentrations of dimethyl sulfoxide and ethanol (below 0.1%, v/v) failed to alter the response of the preparations (data not shown). Phenylephrine, iberiotoxin, and carbachol were dissolved in bidistilled water. Final drug concentrations are stated under Results.
Solutions for I Ca(L) and I Ba(L) Recordings. The external solution contained 130 mM NaCl, 5.6 mM KCl, 10 mM HEPES, 20 mM glucose, 1.2 mM MgCl 2 ⅐ 6 H 2 O, and 5 mM sodium pyruvate (pH 7.4). For cell isolation, external solution containing 20 mM taurine was prepared by replacing NaCl with equimolar taurine. CaCl 2 or BaCl 2 (both 5 mM, final concentration) and tetraethylammonium (30 mM) were added to the external solution for I Ca(L) and I Ba(L) recordings. The internal solution (pCa 8.4) consisted of 100 mM CsCl, 10 mM HEPES, 11 mM EGTA, 2 mM MgCl 2 , 1 mM CaCl 2 , 5 mM sodium pyruvate, 5 mM succinic acid, 5 mM oxalacetic acid, 3 mM Na 2 -ATP, and 5 mM phosphocreatine; pH was adjusted to 7.4 with CsOH. The osmolarity of the 30 mM tetraethylammonium-and 5 mM Ca 2ϩ -or Ba 2ϩ -containing external solution was adjusted to 320 mOsmol and that of the internal solution to 290 mOsmol (Stansfeld and Mathie, 1993) by means of an osmometer (Osmostat OM 6020; Menarini Diagnostics, Florence, Italy).
Solutions for K Ca 1.1 Current Recordings. Solution for enzymatic cell isolation contained 110 mM NaCl, 5 mM KCl, 2 mM MgCl 2 ⅐ 6 H 2 O, 0.16 mM CaCl 2 , 10 mM NaHEPES, 10 mM NaHCO 3 , 0.5 mM KH 2 PO 4 , 0.5 mM NaH 2 PO 4 , 10 mM glucose, 0.49 mM Na 2 EDTA, and 10 mM taurine (pH 7).
Recording solution contained 145 mM NaCl, 6 mM KCl, 10 mM glucose, 10 mM HEPES, 5 mM sodium pyruvate, 1.2 mM MgCl 2 ⅐ 6 H 2 O, 0.1 mM CaCl 2 , and 0.003 mM nicardipine (pH 7.4). Internal solution contained 90 mM KCl, 10 mM NaCl, 10 mM HEPES, 10 mM EGTA, 1 mM MgCl 2 ⅐ 6 H 2 O, and 6.41 mM CaCl 2 (pCa 7.0), pH 7.4. In some experiments, EGTA was replaced by an equimolar concentration of BAPTA.
Solutions for Functional Experiments. The physiological salt solution contained 125 mM NaCl, 5 mM KCl, 2.7 mM CaCl 2 , 1 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 25 mM NaHCO 3 , and 11 mM glucose (pH 7.35).
Statistical Analysis. Acquisition and analysis of data were accomplished by using pClamp 9.2.1.8 software (Molecular Devices Corporation) and Prism version 5.02 (GraphPad Software, Inc., La Jolla, CA). Data are reported as the mean Ϯ S.E.M.; n is the number of cells or rings analyzed (indicated in parentheses) isolated from at least three animals. Statistical analyses and significance as measured by either analysis of variance (ordinary or repeated measures followed by Dunnett's post-test), one sample t test, or Student's t test for unpaired and paired samples (two-tailed) were obtained using InStat version 3.06 (GraphPad Software, Inc.). In all comparisons, p Ͻ 0.05 was considered significant.
Results

Effect of Cardamonin on I Ba(L) and I Ca(L)
. This series of experiments was carried out to evaluate the effect of cardamonin on either I Ba(L) or I Ca(L) and clarify its mechanism of action. Figure 2A , inset, shows average recordings of I Ba(L) elicited with a clamp pulse to 0 mV from V h of Ϫ80 mV under control conditions and after the addition of 15 M cardamonin. Cardamonin inhibited peak I Ba(L) in a concentrationdependent manner with a pIC 50 (M) value of 4.89 Ϯ 0.17 (n ϭ 5) ( Fig. 2A ) that was three orders of magnitude lower than that of nifedipine (7.33 Ϯ 0.05, n ϭ 5) recorded under the same experimental conditions. Cardamonin inhibited the current through Ca v 1.2 channels with a potency that did not depend on the charge carrier. In fact, when equimolar Ca 2ϩ replaced Ba 2ϩ in the external solution, cardamonin pIC 50 (M) value (4.72 Ϯ 0.16, n ϭ 5) ( Fig. 2A) was comparable with that recorded in the presence of Ba 2ϩ . At the maximal concentration tested (100 M), cardamonin inhibited peak I Ca(L) by approximately 76% and peak I Ba(L) by approximately 85%. An even higher fraction of current was inhibited at the end of a 250-ms depolarizing pulse, thereby significantly shifting the inhibition curve to lower concentrations [pIC 50 (M) for Ba 2ϩ of 5.23 Ϯ 0.10, n ϭ 5, p Ͻ 0.05; pIC 50 (M) for Ca 2ϩ of 5.13 Ϯ 0.14, n ϭ 5, p Ͻ 0.05; Student's t test for unpaired samples]. Figure 2B illustrates the time course of the effects of 30 M cardamonin on the current recorded at 0.067 Hz from a V h Ϫ80 mV to a test potential of 0 mV. After I Ba(L) had reached steady values, the addition to the bath solution of cardamonin produced a gradual decrease of the current that reached a plateau in approximately 5 min. Cardamonin-induced inhibition of I Ba(L) and its effect on current kinetics (Fig. 2B , inset) were incompletely reversed upon drug washout (for approximately 10 min).
I Ba(L) evoked at 0 mV from a V h of Ϫ80 mV activated and then declined with a time course that could be fitted by a monoexponential function ( of activation 1.83 Ϯ 0.10 ms and of inactivation 121.94 Ϯ 7.54 ms, respectively; n ϭ 13). In the presence of 15 M cardamonin, both of activation (1.64 Ϯ 0.12 ms, p Ͻ 0.05, Student's t test for paired samples) and of inactivation were significantly accelerated, the latter being better fitted (p Ͻ 0.05) by two rather than by one exponential function (25.74 Ϯ 1.71 and 136.42 Ϯ 9.98 ms, respectively).
The current-voltage relationship (Fig. 3A) shows that 30 M cardamonin significantly decreased the peak inward current and shifted both the maximum from 8.39 Ϯ 0.68 to 0.92 Ϯ 1.71 mV (n ϭ 8; p Ͻ 0.01, Dunnett's post-test) and E rev from 53.26 Ϯ 0.88 to 46.95 Ϯ 3.52 mV (n ϭ 8; p Ͻ 0.05) in the hyperpolarizing direction but without varying the threshold at approximately Ϫ40 mV. Cardamonin-induced inhibition of current-voltage relationship was incompletely reversed upon drug washout (for approximately 10 min), although the maximum and E rev shifted back to the same value of control 
Effects of Cardamonin on Steady-State Inactivation and Activation Curves for I Ba(L) .
The voltage dependence of cardamonin inhibition was assessed by determining the steady-state inactivation and activation curves for I Ba(L) . At a V h of Ϫ80 mV, 15 M cardamonin significantly shifted the steady-state inactivation curve to more negative potentials ( Fig. 3B; Table 1 ). Furthermore, the slope was significantly steeper in the presence of cardamonin.
The activation curves calculated from the current-voltage relationships showed in Fig. 3B , inset, were fitted with the Boltzmann equation (Fig. 3B) . Cardamonin reduced the 50% activation potential without affecting the slope factor (Table  1 ). The shift of both the activation and inactivation curves caused by cardamonin lead to a marked change in the Ba 2ϩ window current that peaked at Ϫ40 mV (with a relative amplitude of 0.051), compared with the peak at Ϫ20 mV (relative amplitude 0.138) observed under control conditions.
Frequency-Dependent Block of I Ba(L) by Cardamonin. To assess the possibility of a frequency dependence of cardamonin action on I Ba(L) , we tested its inhibitory effects during 20 depolarizing pulses of 50-ms length to 0 mV from a V h of Ϫ80 mV applied at stimulation frequencies of 2 or 4 Hz. Under control conditions (no drug), the peak amplitude of I Ba(L) evoked by the 20th pulse decreased significantly as the frequency of stimulation increased only at 4 Hz, thus suggesting an increase in the number of inactivated channels (Fig. 4A) . Seven minutes after drug application, the same protocol was repeated. Cardamonin (15 M) produced a frequency-dependent block of I Ba(L) , which increased with stimulation frequency. Frequency-dependent block, calculated by normalizing the current amplitude evoked by the 20th applied stimulus against that induced by the first step-pulse, was significantly higher than that observed under the corresponding control conditions both at 2 and 4 Hz.
Effects of Cardamonin on Recovery from Inactivation. Many Ca v 1.2 channel blockers inhibit I Ba(L) in a frequency-dependent fashion (use-dependent block). Therefore, the effect of 15 M cardamonin on recovery from inactivation due to conditioning pulses to 0 mV was studied. As shown in Fig. 4B , cardamonin significantly slowed the rate of recovery from inactivation. Furthermore, monoexponential fitting of the plot showed values of 116.90 Ϯ 26.14 (control) and 714.26 Ϯ 181.26 ms (cardamonin; n ϭ 5; p Ͻ 0.05, Student's t test for paired samples), respectively.
Effects of Cardamonin on K Ca 1.1 Currents. Because K Ca 1.1 channels play an important role in the control of myogenic tone in vascular smooth muscle, the effects of cardamonin were assessed also on the K Ca 1.1 current. Under the conditions used in the present experiments, the outward current mostly consisted of iberiotoxin-sensitive K Ca 1.1 cur- Saponara et al., 2006) . Figure 5 , A to C, shows typical recordings of K Ca 1.1 currents elicited with clamp pulses in the range between Ϫ20 and 100 mV from a V h of Ϫ40 mV under control conditions and after the addition of 100 M cardamonin and cardamonin plus 100 nM iberiotoxin. The current-voltage relationships show that cardamonin (Ͼ15 M) increased K Ca 1.1 current in a concentrationdependent manner (Fig. 5D ). To ascertain whether the current recorded in the presence of cardamonin was predominantly carried by K Ca 1.1 channels, we assessed the inhibitory efficacy of iberiotoxin. Indeed, application of 100 nM iberiotoxin reduced to a mere 10% the cardamonin-stimulated current at 100 mV (for example, see Fig. 5C ).
Neither 50 nor 100 M cardamonin modified the rising phase of the currents evoked by depolarizing pulses Ն70 mV. In fact, as shown in Fig. 5E , the traces recorded in the absence or presence of cardamonin (either 50 or 100 M), when sized so that the peak amplitude of all traces matched that of control, were essentially superimposable.
Cardamonin (100 M)-induced stimulation of K Ca 1.1 current was incompletely reversed upon drug washout for approximately 10 min (Fig. 6A) . Although present in the internal solution at a 10 mM concentration, EGTA may be inadequate to buffer submembrane Ca 2ϩ concentrations in such restricted spaces as those between the sarcoplasmic reticulum and the plasma membrane. The effect of cardamonin was therefore tested in the presence of the fast Ca 2ϩ chelator BAPTA at 100 nM free Ca 2ϩ concentration in the internal solution. As shown in Fig. 6B , 100 M cardamonininduced stimulation of K Ca 1.1 current was abolished by BAPTA.
Vasorelaxing Effect of Cardamonin on Tail Artery Rings. To get a direct physiological evidence for either the inhibition of I Ca(L) or the stimulation of K Ca 1.1 current, cardamonin was tested on rat tail artery rings. Cardamonin (1-50 M) induced an almost complete relaxation of endotheliumdenuded rat tail artery rings precontracted either with 1 M phenylephrine or with 10 M (S)-(Ϫ)-Bay K 8644 [efficacy ϭ 93.2 Ϯ 2.7 and 97.0 Ϯ 3.0%, respectively; pIC 50 (M) ϭ 4.63 Ϯ 0.01 and 4.71 Ϯ 0.02, n ϭ 4, respectively] (Fig. 7, A and B) . Iberiotoxin (100 nM) did not affect the concentration-response curve to cardamonin either when phenylephrine [efficacy ϭ 98.8 Ϯ 1.2%; pIC 50 (M) ϭ 4.66 Ϯ 0.04; n ϭ 4; p Ͼ 0.05] or (S)-(Ϫ)-Bay K 8644 was used to contract the vessel [efficacy ϭ 94.8 Ϯ 3.7%; pIC 50 (M) ϭ 4.65 Ϯ 0.04; n ϭ 4; p Ͼ 0.05] (Fig. 7,  A and B) .
Cardamonin (100 M) was also tested for the reversibility of its myorelaxant effect on phenylephrine-induced contraction. After several washes (150 min) with physiological salt solution, phenylephrine-induced contraction partially reverted to 67.8 Ϯ 3.4% control (n ϭ 3).
Discussion
This study provides the first direct evidence that cardamonin is both a Ca v 1.2 channel blocker and a K Ca 1.1 channel stimulator in vascular smooth muscle cells. These findings account, at least in part, for the vasorelaxant effect of the drug previously described by Wang et al. (2001) and confirmed in this study.
Cardamonin acted on vascular Ca v 1.2 channels in a concentration-, voltage-, and frequency-dependent manner, speeded up the time course of current activation, and also shifted the steady-state activation curve to more negative potentials. The latter two effects can be explained assuming that the chalcone modifies the voltage dependence of the channels and interferes with Ca 2ϩ -channel gating kinetics through acceleration (i.e., decreasing the rate constants) of the transition from the closed to the open channel state. Whether these effects are mediated by second messengers or are rather the consequence of a direct action on the channel protein remains to be elucidated by means of single channel analysis. Hz. In absence of cardamonin, 20 depolarizing 50-ms clamp pulses to 0 mV from V h of Ϫ80 mV were applied at 2 or 4 Hz, respectively. Cardamonin was added just after the delivery of the first train of pulses; 7 min later, the same protocol was repeated. The peak amplitude elicited by the first pulse of trains at either frequency (either in absence or in presence of cardamonin) was taken as 100% to better appreciate frequency-dependent block of I Ba(L) . Data points are mean Ϯ S.E.M. (n ϭ 5). ‫,ء‬ p Ͻ 0.05; ‫,ءءء‬ p Ͻ 0.001 versus the 20th pulse recorded in control condition; #, p Ͻ 0.05 versus the 20th pulse recorded in control condition at 2 Hz, Student's t test for paired or unpaired samples, respectively. B, effect of cardamonin on recovery from inactivation. Recovery was obtained using a doublepulse protocol (summarized in inset). Two-second clamp pulse to 0 mV from a V h of Ϫ80 mV (pulse 1; P1) was followed by a second pulse (250 ms) to 0 mV from a V h of Ϫ80 mV (pulse 2; P2). Delay between P1 and P2 (⌬t) was variable in duration. Relative peak I Ba(L) , measured in the absence (control) or presence of cardamonin (15 M), is plotted against recovery interval. Data points represent the mean Ϯ S.E.M. (n ϭ 5). 
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Cardamonin-induced inhibition of I Ba(L) observed at 0.067 Hz, a frequency that allows full recovery between pulses from Ca v 1.2 channel inactivation in rat tail artery myocytes , was tonic in nature and developed independently from channel activation (Kuriyama et al., 1995) . This is interpreted as a consequence of the selective inhibition of the resting channel. However, because the drug significantly accelerated the current decay, the reduced peak current amplitude may partially result from changes in channel gating (see below).
Cardamonin, similar to verapamil (McDonald et al., 1994) , inhibited I Ba(L) in a frequency-dependent fashion (use-dependent block), and, similar to nicardipine (Bean, 1984) , shifted channel availability toward more hyperpolarizing potentials. These effects, conventionally interpreted as the consequence of high-affinity drug-binding to and block of inactivated channels (Bean, 1984) indicate that cardamonin stabilized Ca v 1.2 channels in their inactivated state in a voltage-dependent manner. Such state-dependent action can also explain the greater extent of block observed at the end of a depolarizing pulse compared with the inhibition of peak current. A use-dependent block also may be predicted from the slower recovery from inactivation of drug-bound channels that concomitantly strengthens the hypothesis of a drug-induced stabilization of the inactivated state. In addition, the faster Ca v 1.2 channel inactivation kinetics observed in the presence of cardamonin, reported also for other Ca v 1.2 channel blockers such as dihydropyridines and phenylalkylamines (McDonald et al., 1994) , fitted by two exponentials rather than one probably indicates that the drug, besides unmasking a second inactivation state of the channel, exerts an open channel inhibition (Timin et al., 2004) . Finally, cardamonin caused a significant increase in the slope of the steady-state inactivation curve, thus indicating that the drug altered the sensitivity of the channel inactivation mechanism to membrane voltage. Taken together, these findings indicate that, within the frame of the "state-dependent pharmacology" of the channel, we can assume that three different mechanisms operated by cardamonin simultaneously are responsible for Ca 2ϩ channel block: state-independent (tonic), state-dependent open channel inhibition, and state-dependent inactivated channel inhibition. The "drug-inactivation synergism" model (Hering, 2002) , however, may offer an alternative explanation to these data. In fact, in the frame of this concept, drugs are allowed to bind irrespective of the channel state; drug binding promotes inactivation and delays recovery. In this scenario, enhanced use-dependent channel block results from synergism between drug-induced and intrinsic inactivation.
It is noteworthy that cardamonin caused a marked decrease of the window current. This current is physiologically significant because it is thought to be largely responsible for tone generation and regulation in vascular smooth muscle (Langton and Standen 1993) . Therefore, in in vivo conditions, this feature of cardamonin might reduce steady-state resting vascular tone. Furthermore, cardamonin caused a hyperpolarizing shift of E rev , which might originate from overlapping outward currents brought about by Cs ϩ at very high positive potentials. Both of these phenomena deserve further investigation.
The present data clearly demonstrate that cardamonin, besides its action at Ca v 1.2 channels, significantly increased, in a concentration-dependent manner, the large iberiotoxinsensitive K ϩ outward current in rat tail artery myocytes. Furthermore, the similar K Ca 1.1 channel activation kinetics observed either in the absence or presence of cardamonin indicates that it neither affects the transition from the closed to the open state of the channel nor modifies its gating mechanisms.
When the fast Ca 2ϩ chelator BAPTA replaced EGTA in the internal solution, cardamonin failed to stimulate K Ca 1.1 currents. Therefore, the apparent dependence of K Ca 1.1 channel stimulation induced by cardamonin on local, intracellular Ca 2ϩ concentration might be consistent with an indirect effect of the drug on the channel protein possibly mediated by Ca 2ϩ released from the subplasmalemmal located Ca 2ϩ stores via ryanodine receptors (Jaggar et al., 1998) , although Ca 2ϩ influx via the Na ϩ /Ca 2ϩ exchanger might also contribute to the phenomenon. On the contrary, the contribution of Ca 2ϩ influx via Ca v 1.2 channels has to be ruled out because the present electrophysiological recordings were performed in the presence of nicardipine.
The observation that cardamonin was able to completely relax the tone induced in vessel ring preparations by the well known Ca v 1.2 channel activator (S)-(Ϫ)-Bay K 8644, showing a pIC 50 value similar to that recorded in the electrophysiological experiments, suggests a role for these channels in the mechanism of action of the chalcone. On the other hand, the fact that iberiotoxin did not modify significantly the vasorelaxing effect of cardamonin is not surprising. In fact, the primary role of K Ca 1.1 (or any other K ϩ channel) in vasodilatation is to secure a hyperpolarization large enough to prevent activation of voltage-gated Ca 2ϩ channels. In a situation where vessels are precontracted and subsequently exposed to a compound that both activates K Ca 1.1 and inhibits Ca v 1.2 channels, the function of K Ca 1.1 channel activation will be a secondary inhibition of a Ca v 1.2 channel that is already blocked.
In addition to its antioxidant and anti-inflammatory properties, the present peculiar bifunctional activity [namely stimulation of K Ca 1.1 current and inhibition of I Ca(L) ] exerted on vascular smooth muscle channels renders cardamonin a prospective scaffold for the design of novel drugs of potential interest for the treatment of systemic hypertension. In fact, the microvasculature undergoes extensive biological and morphological adaptation during the pathogenesis of systemic hypertension and other vasospastic diseases. A great number of studies suggest that high blood pressure triggers cellular signaling cascades that dynamically alter the expression profile of arterial voltage-dependent Ca v 1.2 channels, voltage-dependent K ϩ channels (K V ), and K Ca 1.1 channels to further modify vascular tone (Cox and Rusch, 2002) . The excitatory component of this "ion-channel remodeling" phenomenon has been proposed to involve the mutual up-regulation of I Ca(L) (Sonkusare et al., 2006) coupled to the downregulation of K V currents in the arterial plasma membrane. Subsequently, the compensatory overexpression of K Ca 1.1 channels is thought to provide a counter-regulatory mechanism to help avert local vasospasm and ischemic episodes during hypertensive disease. Therefore, designing vasodilator drugs, which bind to ion channels that are highly expressed, would seem a logical approach for developing antihypertensive agents.
Hence, cardamonin that is capable of blocking I Ca(L) and stimulating K Ca 1.1 currents may represent a lead compound for the development of novel vasodilating agents, which target and counterbalance disease-specific changes of ion channel expression, thus lowering vascular tone in hypertensive disease. These results further strengthen the view that dietary polyphenols afford vascular protection (Stoclet et al., 2004) .
